TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07717879: Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-2)

Sponsor: Axsome Therapeutics, Inc. · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 468 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$3,630,088

Rescue Site Savings

+$2,404,344

Unlock Full NCT07717879 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07717879 Rescue Dossier →